| December 1 |
Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call |
| December 1 |
Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers |
| December 1 |
TorreyPines' NGX426 Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects |
| December 1 |
Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model |
| December 1 |
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH |
| December 1 |
Tracking Eye Disorders in Statin Users; Predicting Visual Outcomes for Wounded Soldiers; Improving Glaucoma Tests with Patient Input |
| December 1 |
Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis |
| December 1 |
Study: Patient Harm More Common with Patient-Controlled Pain Medication |
| December 1 |
Experimental TB Drug Explodes Bacteria From The Inside Out |
| December 2 |
TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients |
| December 2 |
Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet |
| December 2 |
GSK and Theravance Announce Positive Phase 2b Results for LABA, '444 in the Horizon Asthma Development Programme |
| December 2 |
Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference |
| December 2 |
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical's Electroporation Technology Shows Safety and Durable Systemic Clinical Response |
| December 2 |
XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease |
| December 2 |
Inovio: final melanoma trial results confirm systemic effect and safety |
| December 2 |
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints |
| December 2 |
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia |
| December 2 |
Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology |
| December 2 |
Gemin X Announces Data Presentations for its Novel, Targeted Cancer Therapy Obatoclax at the 50th Annual American Society of Hematology Meeting and Exposition |
| December 2 |
GENFIT Therapeutic Potential of GFT505 is Demonstrated in the Treatment of Cardiovascular Risk Associated With Pre-Diabetes |
| December 2 |
SuperGen to Present Data at the 50th ASH Annual Meeting & Exposition |
| December 3 |
OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study |
| December 3 |
PN 400 Phase III Studies Show Clinically Meaningful Benefit in Reducing Gastric Ulcers Compared to Enteric-Coated Naproxen |
| December 3 |
POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 Trials |
| December 3 |
Generex Announces Positive Results of Metformin Chewing Gum Trial |
| December 3 |
Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows |
| December 3 |
Celgene Corporation and Acceleron Pharma to Present ACE-011 Data at the 50th Annual Meeting of the American Society of Hematology |
| December 3 |
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting |
| December 3 |
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH |
| December 3 |
Results of Studies of Eslicarbazepine Acetate for the Treatment of Epilepsy to Be Presented at American Epilepsy Society Annual Meeting |
| December 3 |
Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting |
| December 3 |
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study |
| December 3 |
Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 ASH Annual Meeting |
| December 3 |
Nymox Reports Positive New Clinical Trial Data on Improvement in Urinary Urgency and Frequency Symptoms in Patients on NX-1207 Drug for Prostate Enlargement |
| December 3 |
Surprising Results on Smoking Research Hispanic Versus White Female Smokers |
| December 4 |
ConjuChem's PC-DAC:Exendin-4 Lowers Glucose and Weight in Phase II Diabetes Trials |
| December 4 |
Data Demonstrating Significant Efficacy of Viread in Treating Chronic Hepatitis B Published in New England Journal of Medicine |
| December 4 |
EpiCept Reports New Data on Benefits of Maintenance Therapy With Ceplene and interleukin-2 For AML Patients At ASH Annual Meeting |
| December 4 |
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference |
| December 4 |
Data on Stapled Peptide Drugs to Be Presented at ASH Annual Meeting |
| December 4 |
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies |
| December 4 |
Zevalin Data to be Presented at ASH 2008 |
| December 4 |
EpiCept Reports New Data on Benefits of Maintenance Therapy With Ceplene and interleukin-2 For AML Patients At ASH Annual Meeting |
| December 4 |
MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes |
| December 4 |
Starpharma Holdings Limited SPL7013 Shows Activity Against All Major Clinically Relevant Human Papillomavirus (HPV) Strains |
| December 4 |
Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting |
| December 4 |
Inovio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DNA Vaccines at International DNA Vaccines Conference |
| December 4 |
Novelos Therapeutics and Academic Collaborators Present Posters at 2008 AACR Tumor Immunology Conference |
| December 4 |
Archemix Announces ARC1779 Data to Be Presented at Upcoming American Society of Hematology (ASH) Annual Meeting, December 6-9, 2008 |
| December 4 |
Results From the First and Largest Collaborative Study Confirm Role of Enbrel in Psoriatic Arthritis |
| December 4 |
Kiadis Pharma Announces Positive Clinical Results for ATIR in Mismatched Bone Marrow Transplantations - Kiadis Pharma Proceeds with Pivotal Trial ATIR |
| December 5 |
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom 0.09% |
| December 5 |
Novel Basis Identified for Tamoxifen Failure |
| December 5 |
BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition |
| December 5 |
New Data Suggest Cimzia Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease |
| December 5 |
Data on Stapled Peptide Drugs to Be Presented at ASH Annual Meeting |
| December 5 |
GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting |
| December 5 |
New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management |
| December 5 |
Hepatitis C Treatment Reduces the Virus but Liver Damage Continues |
| December 5 |
Vandalia Research to Present DNA Manufacturing Technology at Two Major Vaccine Conferences during December |
| December 8 |
GlycoMimetics, Inc. to Present New Results of Lead Candidate in Additional Animal Models of Sickle Cell Disease at American Society of Hematology Annual Meeting |
| December 8 |
Avila Presents Data on Novel Btk Inhibitor, AVL-101, for B Cell Malignancies |
| December 8 |
Human Genome Sciences to Sponsor Conference Call |
| December 8 |
Human Genome Sciences Announces Albuferon Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C |
| December 8 |
Presentation on Cytopia's JAK2 Inhibitor Program in Myeloproliferative Disorders |
| December 8 |
Exelixis Reports Phase 1 Data for XL019 at ASH Annual Meeting |
| December 8 |
ZIOPHARM Presents Positive Darinaparsin Phase II Data at ASH Meeting |
| December 8 |
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias |
| December 8 |
GPC Biotech Announces Presentation of New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor at the American Society of Hematology Annual Meeting |
| December 8 |
Sosei Confirms the Safety of SD118 in Two Phase I Trials |
| December 8 |
Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma |
| December 8 |
Phase III Trial Results Show Elitek (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome |
| December 8 |
Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures |
| December 8 |
Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma Trial |
| December 8 |
Allos Therapeutics Announces Top Line Results from Pivotal Phase 2 PROPEL Trial of Pralatrexate in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma |
| December 8 |
Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy |
| December 8 |
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer |
| December 8 |
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology |
| December 8 |
Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology |
| December 8 |
Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits in Myelofibrosis Patients |
| December 8 |
Ligand Presents Positive LGD-4665 Clinical Trial Results at theAmerican Society of Hematology Annual Meeting |
| December 8 |
Dynavax Presents Preclinical Data Supporting Its Novel Universal Flu Vaccine Candidate |
| December 8 |
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation |
| December 8 |
Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL |
| December 8 |
Rivaroxaban Reduces Symptomatic VTE & Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of the RECORD Clinical Trial Program |
| December 8 |
Novel Velcade (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients |
| December 8 |
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months |
| December 8 |
Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity |
| December 8 |
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia |
| December 8 |
SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia |
| December 8 |
Vion Pharmaceuticals Presents Additional Survival Data on Onrigin (Laromustine) Injection at ASH Annual Meeting |
| December 8 |
Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008 |
| December 8 |
Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin |
| December 8 |
Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine |
| December 8 |
Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa |
| December 8 |
Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix |
| December 8 |
Zevalin Consolidation in First-Line Therapy in Patients with Non-Hodgkin's Lymphoma Resulted in a Progression-Free Survival of Greater Than 67 Months |
| December 8 |
Gloucester Pharmaceuticals Announces Positive Results from Romidepsin T-cell Lymphoma Clinical Trials at ASH |
| December 8 |
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias |
| December 8 |
Encore Therapeutics Inc. Demonstrates Proof of Concept for a Long-acting Buprenorphine Depot for Pain and Drug Abuse Therapy (ETI-311) |
| December 8 |
Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology |
| December 8 |
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH |
| December 8 |
Exelixis Reports Positive Phase 1 Data for XL228 at ASH Annual Meeting |
| December 8 |
Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug Trial in Patients with Multiple Myeloma |
| December 8 |
Sciele Pharma and Plethora Solutions Announce Final Analysis of PSD502 for Premature Ejaculation; All Primary and Secondary Endpoints Met in Phase III Pivotal Trial |
| December 8 |
Multiple Vimpat (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting |
| December 8 |
Long-term Follow Up Interim Data Show Nplate Increased and Sustained Platelet Counts in Adult Chronic ITP Patients |
| December 8 |
ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate in Drug-Resistant CML Patients with the T315I Mutation |
| December 8 |
Xarelto Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program |
| December 8 |
First Head-to-Head Study Shows that Protelos (Strontium Ranelate) Builds Better Bone Than Bisphosphonate |
| December 8 |
Antisoma Announces Positive Interim Data from AS1411 Phase II Trial in Acute Myeloid Leukaemia |
| December 8 |
Data Presented At ASH Illustrates that Continued Treatment with Vidaza Can Benefit MDS Patients |
| December 9 |
SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial |
| December 9 |
Twenty New Abstracts on Oral Xeloda (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium |
| December 9 |
Soliris Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension |
| December 9 |
Micromet Presents Updated Data on the Phase 1 Trial Studying Blinatumomab (MT103/MEDI-538) in Patients with Advanced Non-Hodgkin's Lymphoma |
| December 9 |
Arzerra (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) |
| December 9 |
ASH Presentation Shows Continued Treatment with Vidaza Improves Responses in Patients with Higher-Risk Myelodysplastic Syndromes |
| December 9 |
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia |
| December 9 |
Video: Tasigna Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia |
| December 9 |
Continued Overall Survival Advantage Reported From Pivotal Trial of Velcade (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma |
| December 9 |
Prolonged Progression-Free Survival Demonstrated by Velcade (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients |
| December 9 |
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma |
| December 9 |
Dyloject Significantly Reduces Moderate-to-Severe Pain in Pivotal Phase 3 Orthopedic Surgical Trial |
| December 9 |
New Keppra XR Data Highlight Its Role for Patients with Partial-Onset Seizures |
| December 9 |
ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Inhibition of All Known Variants of the CML Target Protein Bcr-Abl |
| December 9 |
Exjade Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial |
| December 9 |
Genzyme Reports Clolar Data Further Supporting Potential of Product to Treat Adult AML Patients |
| December 9 |
Dacogen (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML) |
| December 9 |
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath in Patients with High-Risk CLL |
| December 9 |
ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings Reported at ASH Annual Meeting |
| December 9 |
ZymoGenetics Presents Favorable Recothrom Phase 3b Results |
| December 9 |
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs in Treating Post-Operative Pain |
| December 9 |
PolyMedix to Present At HIV DART 2008 on Novel Antimicrobial Compounds for Treatment of Drug Resistant Tuberculosis |
| December 9 |
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology |
| December 9 |
Updated Data Evaluating Clinical Benefit of Revlimid Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma Presented At ASH |
| December 9 |
Study Presented at the American Society of Hematology Reports Revlimid Activity in Patients with Relapsed/Refractory Mantle-Cell Lymphoma |
| December 9 |
Futura Medical Announces Positive Phase I Results for PET500 |
| December 9 |
Arzerra (Ofatumumab) Demonstrates High Response Rates in Patients with Fludarabine Refractory Chronic Lymphocytic Leukaemia (CLL) |
| December 9 |
Targacept Announces Conference Call to be held Today at 5:30 p.m. and Updates Guidance |
| December 9 |
Second-Generation CML Drugs Show Promise as Frontline Therapy |
| December 9 |
Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery |
| December 9 |
Zolinza (vorinostat) in Combination with Bortezomib Showed Clinical Response in Early Investigational Studies of Patients with Relapsed or Refractory Multiple Myeloma |
| December 9 |
Celator Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting |
| December 9 |
ASH Presentation Highlights Durable Responses with Antisoma's AS1413 in Secondary AML |
| December 9 |
Medivation Presents New Data on Dimebon's Novel Mechanism of Action |
| December 9 |
Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG |
| December 9 |
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure |
| December 9 |
Synergy Pharmaceuticals Successfully Completes Phase I Trial of SP-304 in Volunteers |
| December 9 |
Gemin X Presents New Data on Obatoclax at the American Society of Hematology Meeting |
| December 9 |
Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia |
| December 9 |
Velcade (bortezomib) Findings Reinforce Efficacy and Survival Across Multiple Patient Populations |
| December 9 |
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology |
| December 9 |
Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels |
| December 9 |
Intense Chemotherapy Wards off Recurrence in Half of Mantle Cell Lymphoma Patients after Seven Years |
| December 9 |
Updated Revlimid Data in Newly-Diagnosed Multiple Myeloma Reports Unprecedented Three-Year Survival Rates in Phase III ECOG E4A03 Study |
| December 9 |
M. D. Anderson News Release: New Therapy Prevents Dangerous Side Effect for Lymphoma Patients |
| December 9 |
New Data Demonstrate Activity, Combinability of Novel Cancer Therapy Obatoclax - Results Presented at ASH 2008 |
| December 10 |
Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization |
| December 10 |
Alexza's AZ-004 (Staccato Loxapine) Meets Primary Endpoint of Treating |
| December 10 |
Diabetes Drug Shows Potential For Treating One Cause Of Chronic Kidney Disease |
| December 10 |
Consumer Health Sciences Presents Important Data On the Unmet Needs of Depression Patients At the ISPOR 11th Annual European Congress |
| December 10 |
Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia |
| December 10 |
CAL-101, an Oral p110? Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Preclinical Activity in Hematologic Cancer Cells |
| December 10 |
Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers |
| December 10 |
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate |
| December 10 |
PolyMedix Announces Positive Phase I Clinical Data with PMX-30063 Novel Antibiotic Drug Candidate |
| December 10 |
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta |
| December 10 |
Sarah Cannon Research Institute to Present New Trial Results at San Antonio Breast Cancer Symposium |
| December 10 |
MabThera Maintenance Therapy Helps Non-Hodgkin’s Lymphoma Patients Live for Years Longer Without Their Disease Progressing |
| December 10 |
ERYtech Pharma Announces the Results of Its Phase II Clinical Trial |
| December 10 |
Active Biotech's Cancer Project Anyara: Combination with Established Tumor Therapies Promising |
| December 10 |
Promising Results from Two Trials Highlighting Developmental Oral IMiDS Compound Pomalidomide Presented at the American Society of Hematology Meeting |
| December 10 |
GlaxoSmithKline to Present New Tykerb/Tyverb (Lapatinib) Data at SABCS 2008 |
| December 10 |
New Data Evaluating Abraxane in Early-Stage Breast Cancer and in Combination with Novel Investigational Agents to Be Presented at SABCS |
| December 11 |
Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans |
| December 11 |
Qnexa Meets Primary Endpoint by Demonstrating Superior Weight Loss over Components and Placebo in the 28-Week Equate Study (OB-301) |
| December 11 |
Data from Eight Clinical Trials Facilitated by the Multiple Myeloma Research Consortium (MMRC) Presented at the American Society of Hematology (ASH) Annual Meeting |
| December 11 |
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009 |
| December 11 |
Oncolytics Biotech Inc.'s Reolysin Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study |
| December 11 |
Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate |
| December 11 |
Femara First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery |
| December 11 |
PolyMedix Announces Positive Phase I Clinical Data |
| December 11 |
Oncolytics Biotech Inc.'s Reolysin Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study |
| December 11 |
CST New Data Show Zometa Enhances Impact of Chemotherapy on Reducing Breast Tumor Size |
| December 11 |
Combination of Tykerb (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer |
| December 11 |
Pfizer Announces Results from Trial of Aromasin in Postmenopausal Women with Hormone Sensitive Early Breast Cancer |
| December 12 |
Qnexa Reduces Hemoglobin A1c By 1.6% in 56 Weeks |
| December 12 |
SARcode Announces Completion of Phase 1 Clinical Trial of SAR 1118 Ophthalmic Solution |
| December 12 |
Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium |
| December 12 |
New Data from Largest-Ever Clinical Trials in CLL Show Rituxan (Rituximab) Enables Leukemia Patients to Live Longer Without Their Disease Progressing |
| December 12 |
Gleevec Leads to Longest Survival Reported for Patients with Life-threatening Form of Leukemia, 7-year IRIS Data Show |
| December 12 |
Lexicon's Drug Candidate LX6171 for Cognitive Disorders Completes Phase 2A Clinical Trial |
| December 12 |
K-State Researcher Finds Correlation Between Childhood Obesity and Asthma |
| December 12 |
Ablynx Reports Positive Phase Ib Results for its Anti-Thrombotic Nanobody ALX-0081 |
| December 12 |
First Phase III Results for FTY720, a Novel Oral Therapy for MS, Show Superior Efficacy Compared to Interferon Beta-1a |
| December 12 |
Novelos Therapeutics Announces Presentation of Positive Results in Ongoing Phase 2 Neoadjuvant Breast Cancer Trial at San Antonio Breast Cancer Symposium |
| December 12 |
Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer |
| December 15 |
RAD001 Shows Potential to Reverse Resistance to Herceptin in Metastatic Breast Cancer Patients, Leading to Phase III Trial |
| December 15 |
Theratechnologies Reports 52-week Confirmatory Phase 3 Results |
| December 15 |
Theratechnologies Reports 52-week Results in its Confirmatory Phase 3 Trial with Tesamorelin |
| December 15 |
Study Finds Doxil Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer |
| December 15 |
Positive Phase II Study of Pacira's Exparel (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA) |
| December 15 |
Abraxane in Combination with Gemcitabine and Epirubicin Evaluated as Neoadjuvant Treatment for Patients with Locally Advanced Breast Cancer |
| December 15 |
Alexion Reports Positive Results From Aegis Registration Study Of Soliris In Japanese Patients With PNH |
| December 15 |
Study Finds Doxil Combination Therapy Delays Disease Progression for Patients with Metastatic Breast Cancer |
| December 16 |
Antisoma plc (UK) - Phase II trial showing improved survival with ASA404 in lung cancer published in British Journal of Cancer |
| December 16 |
MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes |
| December 16 |
QLT announces interim results of radical study evaluating Visudyne combination therapy |
| December 16 |
US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium |
| December 16 |
Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on Xerecept Clinical Program and Planned Sale in 2009 |
| December 16 |
Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery |
| December 16 |
Nymox Releases New Study Data from U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Which Shows Significantly Less Interruption of Sleep For Men Given Nymox Drug |
| December 17 |
NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis |
| December 17 |
Starpharma Holdings Ltd (ASX:SPL) Dendrimer Reduces Toxicity of Cancer Drug |
| December 17 |
Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID |
| December 17 |
Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery |
| December 17 |
Lead Drug In Phase 3 Trial Has Potential To Be First FDA-Approved Prescription Topical NSAID Cream Product |
| December 17 |
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer's Compound Anavex 1-41 Published in Journal of Neuropsychopharmacology |
| December 18 |
MannKind Reports Top-Line Results from Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes |
| December 18 |
CrystalGenomics Announces Positive Phase IIa Results for Osteoarthritis Study of CG100649 |
| December 18 |
New Analysis of Discovery Labs' Phase 3 RDS Trials Identifies Reintubation as Key Risk Factor for Infant Mortality |
| December 18 |
ARYx Therapeutics, Inc. Announces Successful Outcome of Atrial Fibrillation Clinical Trial on ATI-2042 |
| December 18 |
ACE-011 Phase 1 Results Published in the Journal of Bone and Mineral Research |
| December 18 |
Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis |
| December 18 |
Arete Therapeutics Reports Positive Phase I Data for AR9281 |
| December 18 |
Common Treatment for Chronic Prostatitis Fails to Reduce Symptoms |
| December 19 |
NicOx' Naproxcinod Shows Differentiated 24-Hour Blood Pressure Profile After 13 Weeks Treatment |
| December 19 |
Phase III Study Showed Rituxan Decreased the Progression of Joint Damage in Patients with Early Rheumatoid Arthritis (RA) |
| December 19 |
Arpida Publishes Top-Line Data of Phase II "Intravenous-To-Oral" Switch Trial With Oral Iclaprim |
| December 19 |
Memory Pharmaceuticals Reports Phase 1 Data for R4996/MEM 63908 |
| December 19 |
Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times |
| December 19 |
Biofrontera AG (DE) - Ad hoc: Biofrontera AG: Excellent Phase III-results with BF-200 ALA |
| December 19 |
MabThera inhibits the destruction of joints in patients with early rheumatoid arthritis |
| December 22 |
BioCryst Pharmaceuticals Continues Forodesine HCl Program in Chronic Lymphocytic Leukemia |
| December 22 |
RegeneRx Updates Schedule for Release of Clinical Trial Information |
| December 22 |
Pre-clinical Research on EVATAK in Human Gastric (Stomach) Cancer Accepted for Publication |
| December 22 |
GSK and Theravance Announce Positive Phase 2b Results for LABA '444 in the Treatment of COPD in the Horizon Development Programme |
| December 23 |
ImmunoCellular Therapeutics' Cancer Vaccine Demonstrates Immune Response Against Brain Cancer in Clinical Trial |
| December 23 |
Molecular Insight's Zemiva Demonstrates Ability to Improve Early Diagnosis of the Chest Pain Patient in the Emergency Department |
| December 23 |
NicOx Announces Results for TPI 1020 in COPD |
| December 23 |
Dionysos Study Results Showed The Respective Profiles of Dronedarone and Amiodarone |
| December 23 |
ImQuest Presentations at International HIV Meeting Highlight Significant Progress in Their Therapeutic and Microbicide Development Programs |
| December 23 |
Napo Pharmaceuticals Announces Publication of Paper on Crofelemer for Indication of Irritable Bowel Syndrome |
| December 23 |
Northwest Biotherapeutics Reports Encouraging Data on First Patients Who Have Completed Its Phase I/II Clinical Trial of DCVax-L in Metastatic Ovarian Cancer |
